Voyager Therapeutics, Inc. (VYGR)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are below the required floor of 3, and the stock also fails both liquidity gates.
Company overview
Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments for neurological diseases. Its lead clinical asset, VY-AADC, is in Phase 1 trials for Parkinson's disease. The company collaborates with industry partners like Neurocrine Biosciences, Pfizer, and Novartis to advance its gene therapy pipeline.
Fundamental
weakVoyager's strong liquidity contrasts with its speculative business model reliant on clinical progress and partnerships.
Voyager is an early-stage biotech with no interest-bearing debt and strong liquidity (current ratio ~7.5x; ~$149M cash/marketable securities at 6/30/2026). But revenue has been volatile/declining (FY2023 $250.0M → FY2025 $40.4M) and cash burn remains heavy (FY2025 operating cash flow −$132.5M), leaving meaningful clinical-trial and potential future financing/dilution risk. Fundamentally it fits better as a high-uncertainty, catalyst-driven watchlist name than a steady compounding business today.
Sentiment
weakRecent media sentiment has turned negative post-earnings, with no clear bullish catalysts in the near term.
Last ~14d media tone has flipped negative after the Aug 6 Q2 update (loss/revenue miss framing and cash-runway focus), with polarity_score ≈ -0.26 versus a bullish 30–90d baseline (≈ +0.45) that centered on FDA IND clearance and trial-start headlines. Moderate red-flag cap applied due to the sharp sentiment deterioration with no clear forward bullish catalyst; legal/regulatory screens show no regulator-confirmed investigations and Reddit chatter is effectively absent.
Technical
weakDespite a short-term rebound, the broader trend is down with insufficient liquidity for an actionable trade.
Reclaimed short-term averages and a positive MACD histogram improve the near-term tape, yet price remains below the 50/200-day averages, MACD is still under zero, and ADX is weak, so this looks like a bounce instead of a durable breakout.
You’re looking at 2026-08-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.